SINTX TECHNOLOGIES SIGNIFICANTLY STRENGTHENS ITS ANTIPATHOGENIC PATENT PORTFOLIO

SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT; “SINTX” or the “Company”), a manufacturer and developer of advanced ceramic materials and related technologies, announced that it has been granted its sixth United States patent in the last year. All of these United States patents are related to the antipathogenic properties of silicon nitride.

The six United States patents granted to SINTX are:

• 11,591,217; Antipathogenic Devices and Methods Thereof
• 11,672,252; Antifungal Composites and Methods Thereof
• 11,738,122; Antibacterial Biomedical Implants and Associated Materials, Apparatus, and Methods
• 11,844,344; Systems and Methods for Rapid Inactivation of SARS-COV-2 by Silicon Nitride and Aluminum Nitride
• 11,850,214; Antiviral Compositions and Devices and Methods of Use Thereof
• 11,857,001; Antipathogenic Face Mask

The significance of the six mentioned patents lies in their innovative approaches towards utilizing silicon nitride (Si₃N₄) in a wide range of antipathogenic solutions. The surface antipathogenic properties of silicon nitride have been published extensively in the peer literature by SINTX as well as by outside investigators.

The first two patents (US Patent Nos. 11,591,217 and 11,672,252) cover slurries and composites of silicon nitride with polymethyl methacrylate (PMMA) for use in combating fungal infections in plants and preventing fungal colonization of medical implants - including specific applications in dentistry. The third patent (US Patent No. 11,738,122) describes implants comprised of polymeric and titanium materials coated with SiYAlON (a subclass of silicon nitride materials) as well as implants made from composites of SiYAlON and polymers like polyetheretherketone (PEEK) as candidates for reducing infection burden in biomedical applications. (These coating and composite technologies are the foundation for recent and ongoing NIH-funded commercialization work at SINTX.) The fourth patent (US Patent No. 11,844,344) presents a method for rapid inactivation of viruses using silicon nitride in various objects such as protective gear used by medical personnel. The fifth patent (US Patent No. 11,850,214) extends the antiviral composition to include various silicon nitride materials, thereby offering versatility in forms like slurry or spray applicable to medical devices. The final patent (US Patent No. 11,857,001) emphasizes an antipathogenic face mask containing silicon nitride and capable of inactivating human viruses.